今日主要股指延续震荡整理态势，上证指数收涨0.16%，报4157.98点；深证成指跌0.3%，创业板指跌 0.57%，北证50跌1.69%，科创50跌3.03%。A股全天成交额3.26万亿元，较上一交易日2.99万亿元进一步 放量。个股表现明显分化，超3500只个股收跌。分板块来看，白酒、传媒、黄金、油气等板块涨幅居 前，半导体产业链则出现不同程度回调。 今日贵金属板块持续走强。伦敦金现价格逼近5600美元/盎司，伦敦银现价格一度突破120美元/盎司， 黄金ETF（518800）收涨5.49%。今日凌晨，美联储召开1月FOMC会议，决议维持基准利率不变。会后 美联储主席鲍威尔发言措辞克制，回避了多项政治敏感话题，试图稳定市场信心。但市场仍在博弈美联 储独立性受损及降息政策路径混乱的担忧。叠加地缘风险升温，显著推升黄金避险溢价。此外，全球央 行购金潮持续、"去美元化"进程加速形成结构性支撑，黄金中长期向好逻辑仍在持续强化。需注意的 是，当前国际黄金现货RSI指标处于高位，波动率指数创下近十年峰值，短期需警惕回调风险。 （风险提示：提及个股仅供参考，不作为股票推荐，不构成投资建议和承诺。指数/个股短期涨跌仅供 参 ...

Group 1 - The market anticipates the Federal Reserve will begin a new rate-cutting cycle on September 17, 2025, influenced by recent economic data indicating a softening job market and a moderated inflation rate, providing more room for rate cuts [1][3] - Gold is identified as a key asset benefiting from the expected rate cuts, with historical data showing strong performance during previous rate-cutting cycles, such as a 24% increase in gold prices in 2020 [1][4] - Central banks, particularly the People's Bank of China, have been increasing gold reserves for ten consecutive months, enhancing market demand for gold [1][4] Group 2 - Investors are encouraged to consider gold ETFs, such as the one tracking the AU9999 spot contract, which allows for T+0 trading, and gold stock ETFs that cover the entire gold industry chain [2] - The Hong Kong stock market is expected to benefit from global liquidity easing, with a potential rebalancing of global funds from dollar assets to Asian assets, particularly in technology and innovative drug sectors [2] - In the U.S. market, the anticipated rate cuts and expectations of a "soft landing" may lead to performance growth in tech giants driven by AI technology, although macroeconomic uncertainties could increase market volatility [3]

Market Overview - Major indices experienced a significant decline, with the Shanghai Composite Index falling by 0.94% to 3348.37 points, and the Shenzhen Component Index down by 0.85% [1] - A total of 4200 stocks declined, with an increasing number of stocks hitting the daily limit down [1] - The total trading volume in A-shares reached 1.18 trillion yuan, slightly up from 1.14 trillion yuan the previous day [1] Pharmaceutical Sector Performance - The pharmaceutical sector showed resilience, with AI medical and innovative drugs performing well [2] - The ETF for innovative drugs on the ChiNext (国泰159377) rose by 1.27%, while the innovative drug ETF (沪深港ETF 517110) increased by 0.50% [1] - Chinese innovative drug companies demonstrated significant technological breakthroughs in ADC and bispecific antibodies, as highlighted by the 2025 ASCO summary data [1] - Notable performances included Zai Lab's ZG005 in cervical cancer and Huahai Pharmaceutical's HB0025 in endometrial cancer, both exceeding expectations [1] AI Medical Development - The year 2025 is anticipated to be a pivotal year for the rapid development of AI in healthcare, supported by a government plan aiming for full digital transformation in the pharmaceutical industry by 2030 [2] - Factors such as AI empowerment across the pharmaceutical supply chain, optimization of domestic procurement policies, and recovery in medical equipment tenders are expected to boost sentiment and valuation in the pharmaceutical sector [2] Gold Market Insights - Gold stocks rebounded in the afternoon, with the gold stock ETF (517400) rising by 0.8% and the gold ETF (518800) increasing by 0.05% [2] - The global rise in uncertainty has reignited safe-haven demand for gold, leading to price recovery [2] - The trend of "de-dollarization" globally is expected to enhance gold's role as a pricing anchor, with central banks continuing to increase gold reserves [4] Investment Opportunities - Investors are encouraged to consider the innovative drug ETFs (517110 and 159377) due to the high research highlights and accelerating commercialization trends in innovative drugs [2] - For gold investments, the gold fund ETF (518800) and its linked funds are recommended for gradual accumulation during price corrections, as gold stocks are currently valued at historical lows [5]